Willa A. Hsueh, M.D., Joins Bionovo's Scientific Advisory Board
EMERYVILLE, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Bionovo, Inc.
(Nasdaq: BNVI) announced today the appointment of Willa Hsueh, M.D., to the
company's Scientific Advisory Board. Dr. Hsueh has extensive experience in the
design and conduct of clinical trials, basic science research and in
pharmaceutical drug development.
"We are very excited to have Dr. Hsueh on the scientific advisory board as
we are advancing our discovery platforms," said Isaac Cohen, O.M.D., Bionovo's
Chairman and CEO. "Dr. Hsueh is currently the Director of the Diabetes
Research Center at The Methodist Hospital Research Institute and Chief of the
Division of Diabetes, Obesity and Lipids in the Department of Medicine at The
Methodist Hospital (TMHRI), Houston, Texas. Dr. Hsueh's research has led to a
number of important scientific discoveries. She was the first to elucidate the
relationship between nuclear receptor regulation in obesity and diabetes and
their relationship to heart disease. This scientific advancement is especially
critical for menopausal women and Dr. Hsueh's research ties into Bionovo's
current drug discovery platform as well as our future platform development of
drugs for obesity. In addition, Dr. Hsueh's deep relationships in both
industry and academia will help Bionovo with our partnership discussions and
Dr. Hsueh adds, "I am looking forward to working with Bionovo's
exceptional team on their very exciting nuclear receptor discovery platform.
The scientific group that has been assembled to collaborate with Bionovo is
unmatched in the industry. I believe the very promising pipeline of Bionovo
drug candidates will provide new and improved therapies for women."
Dr. Hsueh and her team were the first to identify a potentially protective
role for the activation of nuclear receptors of the peroxisome proliferator
activated receptor family (PPAR) in vascular injury. Dr. Hsueh was one of the
earliest investigators to suggest that diabetes is a major contributor to
cardiovascular injury, and she has been dedicated to identifying biomarkers
and genetic defects associated with increased risks for diabetes and
Dr. Hsueh has received many awards in recognition of her clinical and
scientific work. In 2005 she received the Edwin B. Astwood Award from the
Endocrine Society for Outstanding Research. She also received the National
Institute of Arthritis, Metabolism and Digestive Diseases, MERIT Award from
1991- 1998, the American Heart Association, Harry Goldblatt Award for
Cardiovascular Research in 1986 and The Upjohn Achievement Award for Research
in 1973. Prior to becoming the Director of the Diabetes Research Center at The
Methodist Hospital Research Institute and Chief of the Division of Diabetes,
Obesity and Lipids in the Department of Medicine at The Methodist Hospital
(TMHRI), Houston, Texas earlier this year, Dr. Hsueh was the Chief of the
Division of Endocrinology, Diabetes and Hypertension at the University of
California, Los Angeles (UCLA) from 1997 to 2008. In addition to her academic
and administrative duties, Dr. Hsueh maintains a full clinical practice and is
involved in many translational research projects.
Bionovo is a pharmaceutical company focused on the discovery and
development of safe and effective treatments for women's health and cancer,
markets with significant unmet needs and billions in potential annual revenue.
The company applies its expertise in the biology of menopause and cancer to
design new drugs derived from botanical sources which have novel mechanisms of
action. Based on the results of early and mid-stage clinical trials, Bionovo
believes they have discovered new classes of drug candidates within their rich
pipeline with the potential to be leaders in their markets. Bionovo is
headquartered in Emeryville, California and is traded on the NASDAQ Capital
Market under the symbol, "BNVI". For more information about Bionovo and its
programs, visit: http://www.bionovo.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to the
business of Bionovo, Inc. that can be identified by the use of forward-looking
terminology such as "believes," "expects," or similar expressions. Such
forward-looking statements involve known and unknown risks and uncertainties,
including uncertainties relating to product development, efficacy and safety,
regulatory actions or delays, the ability to obtain or maintain patent or
other proprietary intellectual property protection, market acceptance,
physician acceptance, third party reimbursement, future capital requirements,
competition in general and other factors that may cause actual results to be
materially different from those described herein as anticipated, believed,
estimated or expected. Certain of these risks and uncertainties are or will be
described in greater detail in our filings with the Securities and Exchange
Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under
no obligation (and expressly disclaims any such obligation) to update or alter
its forward-looking statements whether as a result of new information, future
events or otherwise.
SOURCE Bionovo, Inc.
/CONTACT: Claire Fong or Tom Chesterman, both of Bionovo, Inc.,
/Web site: http://www.bionovo.com /
CO: Bionovo, Inc.
IN: HEA MTC
-- AQM105 --
8756 12/15/2008 15:00 EST http://www.prnewswire.com